Brian Laegeler
-
Novartis Presents a Bullish Options Opportunity
… and the Jan. 4 note . We also want to acknowledge the terrific work of Morningstar's coverage analyst for Alcon, Brian Laegeler , who has long been saying that Alcon would likely be fully acquired by Novartis, and whose fair value estimate is …
-
Generic Biologics Face Uphill Battle -- Part 2Brian Laegeler : I think from your perspective, you have seen some of the differences in your coverage list between traditional generics and …
Brian Laegeler : I think from your perspective, you have seen some of the differences in your coverage list between traditional generics and biologics. -
Generic Biologics Face Uphill Battle… an opportunity here? With me today to discuss the topic is generic pharmaceuticals analyst Brian Laegeler . Thanks for joining me, Brian. Brian Laegeler : Thanks for having me. Andersen : What is going on in Washington right now? Why hasn …
here? With me today to discuss the topic is generic pharmaceuticals analyst Brian Laegeler . Thanks for joining me, Brian. Brian Laegeler : Thanks for having me. Andersen : What is going on in Washington right now? Why hasn't there been any legislation passed -
Our Take on IPO Cumberland's Growth Prospects… is looking to raise $100 million. Joining me today is specialty pharma analyst Brian Laegeler to talk about Cumberland. Brian, thanks for coming. Brian Laegeler : Thanks for having me. Buhr : Now, where does Cumberland fit into specialty …
looking to raise $100 million. Joining me today is specialty pharma analyst Brian Laegeler to talk about Cumberland. Brian, thanks for coming. Brian Laegeler : Thanks for having me. Buhr : Now, where does Cumberland fit into specialty pharma? Laegeler : Well, Cumberland is a specialty -
A Quintet of Bargain Stocks
… to our fair value estimate. At these prices, there should be enough value to go around for all parties involved. Brian Laegeler Angiotech Pharmaceuticals Highlights Pipeline (Maintaining) Angiotech Pharmaceuticals ANPI reported decent first …
-
Four New Stocks on Sale
… manufacturing cost advantage has dissipated with the appreciation of the Canadian dollar. While Morningstar analyst Brian Laegeler believes the business could be worth as much as $20 per share to a large competitor, the family controls almost …
-
Eight New Stocks on Sale
… manufacturing cost advantage has dissipated with the appreciation of the Canadian dollar. While Morningstar analyst Brian Laegeler believes the business could be worth as much as $20 per share to a large competitor, the family controls almost …
-
Democrat-Proof Health-Care Stocks
… will be much longer, the Democrats are creating several possible bills that could accelerate these changes. From Brian Laegeler 's Analyst Report : "Hospira is a well-established hospital supply business with wide-moat potential …
-
The Week in Stocks: AMD and 3M Issue Warnings
… Tele Norte Leste Analyst Report: Vivo Participacoes Big Pharma Playing Rough with Generic Drugmakers As analyst Brian Laegeler wrote in his recent analysis of generic drug-maker Teva Pharmaceuticals TEVA, big pharma is taking a novel new …
-
Biogen Idec-Elan MS Drug Is Back
… Serono SRA, Biogen's competitor in the multiple sclerosis market. While Tysabri may lure some patients away from Serono's Rebif, restrictive FDA safety guidelines reduce Tysabri's threat. Brian Laegeler contributed to this note.